***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: Introduction : Aflibercept ( vascular endothelial growth factor [ VEGF ] trap ) , a recombinant fusion protein , blocks the activity of VEGF-A and placental growth factor and has demonstrated activity in pretreated patients with lung cancer in a phase I trial . This study evaluated the efficacy and safety of intravenous aflibercept in patients with platinum- and erlotinib-resistant lung adenocarcinoma . Methods : An open-label , single arm , multicenter trial was conducted , with the primary end point of response rate ( modified RECIST ) . Additional endpoints included safety , duration of response , progression-free survival , and overall survival .  Patients with platinum- and erlotinib-resistant lung adenocarcinoma were eligible .  Aflibercept 4.0 mg/kg intravenous every 2 weeks was administered until progression of disease or intolerable toxicity . Results : Ninety-eight patients were enrolled ; 89 were evaluable for response . Median age was 60 years , 41 % were men with Eastern Cooperative Oncology Group performance status 0/1/2 in 35/55/9 % of patients . The overall response rate was 2.0 % , ( 95 % confidence interval , 0.2 - 7.2 % ) . Median progression-free survival was 2.7 months , and overall was survival 6.2 months . Six- and 12-month survival rates were 54 and 29 % , respectively . A median of four cycles was administered ( range 1 - 22 ) . Common grade 3/4 toxicities included dyspnea ( 21 % ) , hypertension ( 23 % ) , and proteinuria ( 10 % ) . Two cases of grade 5 hemoptysis were reported , and one case each of tracheoesophageal fistula , decreased cardiac ejection fraction , cerebral ischemia , and reversible posterior leukoencephalopathy . Conclusions : Aflibercept has minor single agent activity in heavily pretreated lung adenocarcinoma , and is well tolerated , with no unexpected toxicities . Further studies evaluating aflibercept in lung cancer , in combination with chemotherapy and other targeted therapies , are ongoing PURPOSE Development of new therapies for previously treated small-cell lung cancer ( SCLC ) is a major unmet need . Here , we describe a r and omized , phase II trial of weekly topotecan with or without ziv-aflibercept ( VEGF-trap ) in this clinical setting . PATIENTS AND METHODS Patients with previously treated SCLC ( one line of platinum-based chemotherapy ) , performance status of 0 to 1 , adequate organ function , treated brain metastases , and no recent vascular events or bleeding diatheses were eligible . Eligible patients were stratified as platinum-sensitive or platinum-refractory and r and omly assigned to receive weekly topotecan 4 mg/m(2 ) intravenously ( IV ) with or without ziv-aflibercept 6 mg/kg IV every 21 days . Progression-free survival ( PFS ) at 3 months was the primary end point . RESULTS In 189 r and omly assigned patients , treatment arms were well balanced with regard to clinical characteristics . The 3-month PFS was significantly improved with the addition of ziv-aflibercept in patients who had platinum-refractory disease ( 27 % v 10 % ; P = .02 ) but not in patients with platinum-sensitive disease ( 24 % v 15 % ; P = .22 ) . Although response rate was low , disease control rate was higher with combination therapy than with topotecan alone in patients who had platinum-sensitive disease ( 37 % v 18 % ; P = .05 ) and in those who had platinum-refractory disease ( 25 % v 15 % ; P = .14 ) . Overall survival ( OS ) was not significantly improved in either strata . Grade s 3 to 5 toxicities were more common with the addition of ziv-aflibercept . CONCLUSION Ziv-aflibercept improved the 3-month PFS in patients who had platinum-refractory SCLC , but its addition increased toxicity . OS was similar with combined ziv-aflibercept and topotecan compared with topotecan in both strata 
    Output:
    
Furthermore , the risk of infections with aflibercept was substantially higher than bevacizumab .
CONCLUSIONS Aflibercept is associated with a significant increased risk of developing severe infections in patients with solid tumours .